An independent resource on ibogaine research, policy, and safety.

Services

Guides, comparisons, and research summaries for people seeking grounded context on ibogaine—built to distinguish preliminary findings from established evidence and regulated care.

Symbolic still life accompanying an evidence-first guide to ibogaine research, policy, and safety

01 / Guides

Research summaries with the uncertainty left in.

Our in-depth guides organize research questions, study designs, and limits in plain language. The aim is not to convert emerging findings into certainty, but to make the difference visible for patients, families, policymakers, researchers, and community members.

Ibogaine is a psychoactive alkaloid associated with Tabernanthe iboga, a plant with cultural and historical context that should not be flattened into a product claim. For a wider orientation to the subject, begin with our grounded ibogaine research and safety context.

02 / Frameworks

Decision frameworks for difficult questions.

Our comparison and decision materials help readers separate legal status, research interest, safety concerns, and access claims without treating any one category as a substitute for another. They are informational tools, not medical or legal advice.

Questions about policy benefit from careful definitions: the DEA’s drug scheduling overview is one official starting point for understanding the United States framework. Our approach to sourcing and independence explains how Steady Lantern 35 handles uncertainty and changing public questions.

Abstract composition accompanying decision frameworks for evaluating ibogaine information

Useful context does not erase risk. It gives risk its proper place in the decision.

Steady Lantern 35 · Independence · Evidence before hype · Risk clarity

03 / Comparisons

Set the claims beside the questions they need to answer.

Research summaries

What was studied, how it was studied, and what the evidence can—and cannot—support.

Safety context

How reported risks, screening language, interactions, and uncertainty should be read with care.

Policy context

How rules, enforcement, and public discussion differ across jurisdictions and over time.

04 / Context

Comparative reading across public questions.

Some readers arrive through aging, neurodegenerative disease, or sport-specific conversations. We keep those topics in context: brain and aging questions, ALS-focused discussion, and basketball-related public questions each require different evidence standards and should not be treated as outcome claims.

The same caution applies when looking at soccer community conversations or hockey-related perspectives: a compelling story is not the same thing as established evidence. These materials are intended to make that distinction easier to retain.

05 / FAQ

Clearer questions, not clinical promises.

Do these materials recommend treatment?

No. Steady Lantern 35 is an independent information resource. We do not provide medical care, legal advice, treatment recommendations, or clinical outcomes. When readers encounter provider claims, a framework for reviewing treatment clinic information can help keep practical questions separate from promotional language.
Why are safety updates treated separately from research?

Research interest does not establish safety in every setting or for every person. The U.S. Food and Drug Administration describes its role in evaluating drug safety and effectiveness through its drug development and approval process; that distinction is useful when reading early findings or public claims.
Who are these information services for?

They are for people seeking grounded context on ibogaine, including patients, families, policymakers, researchers, and community members. The materials prioritize plain language, cultural respect, and careful attention to what is known, unknown, and changing.

Use the material as a starting point for better questions—not as a substitute for qualified medical, legal, or regulatory guidance.

Explore safety & evidence